SCHEMBL6087420

SCHEMBL6087420

NC(=O)NCC1O/C(=C2\C(=O)Nc3ccccc32)c2ccccc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAOK1 Q7L7X3 1/20 0.35
IDO1 P14902 3/20 0.35
TDO2 P48775 1/20 0.35
HSD17B10 Q99714 3/20 0.34
ALDH1A1 P00352 4/20 0.34
MAPT P10636 3/20 0.34
MAPK1 P28482 2/20 0.34
KDM4E B2RXH2 1/20 0.34
PKM P14618 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
LRRK2 Q5S007 2/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
PDGFRA P16234 1/20 0.33
FER P16591 1/20 0.33
LTK P29376 1/20 0.33
CDK8 P49336 1/20 0.33
ACVR1 Q04771 1/20 0.33
DYRK1B Q9Y463 1/20 0.33
NTRK1 P04629 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6087424 1.00 TAOK1 (0.35) TAOK1IDO1TDO2HSD17B10ALDH1A1
SCHEMBL14725043 1.00 TAOK1 (0.35) TAOK1IDO1TDO2HSD17B10ALDH1A1
SCHEMBL6086708 0.86 HSD17B10 (0.46) IDO1TDO2HSD17B10ALDH1A1MAPT
SCHEMBL6086705 0.86 HSD17B10 (0.46) IDO1TDO2HSD17B10ALDH1A1MAPT
SCHEMBL6086948 0.85 IDO1 (0.45) IDO1TDO2HSD17B10ALDH1A1MAPT
SCHEMBL6087058 0.85 TAOK1 (0.33) TAOK1IDO1TDO2HSD17B10ALDH1A1
SCHEMBL14725077 0.85 TAOK1 (0.33) TAOK1IDO1TDO2HSD17B10ALDH1A1
SCHEMBL6086950 0.85 IDO1 (0.45) IDO1TDO2HSD17B10ALDH1A1MAPT
SCHEMBL6087055 0.85 TAOK1 (0.33) TAOK1IDO1TDO2HSD17B10ALDH1A1
SCHEMBL6104185 0.82 OPRM1 (0.44) TAOK1ALDH1A1MAPTLRRK2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490356-B1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN INC (US) 2013-02-27 EP disclosed
US-7060844-B2 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-06-13 US disclosed
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-01-05 US disclosed
EP-1490356-A1 (3Z)-3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1,3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS Allergan, Inc. (US) 2004-12-29 EP disclosed
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2004-01-29 US disclosed
WO-2003084951-A1 (3Z) -3-(3-HYDRO-ISOBENZOFURAN-1-YLIDENE)-1, 3-DIHYDRO-2H-INDOL-2-ONES AS KINASE INHIBITORS ALLERGAN, INC. (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004084-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 TAOK1 713/4885IDO1 213/4885TDO2 751/4885
US-20040019098-A1 (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors CDK2, ERBB2, MAP3K3 TAOK1 727/4885IDO1 235/4885TDO2 780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.